-
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors
The purpose of the study is to evaluate the safety and immunogenicity of NM21-1480 in specific tumor types. We wish to know the maximum tolerated ... -
A Phase 1/2 Open-label Study to Investigate the Safety Efficacy and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
This study is designed for patients diagnosed with relapsed or refractory B cell precursor acute lymphoblastic leukemia (R/R B-ALL).
This study is a 2-part ...
-
A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C
This study is designed for patients with acute myeloid leukemia.
The study is a phase 1/2 dose escalation study of the BCL-2 Inhibitor ZN-d5 ...
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
-
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.
The ...
-
New Pfizer Shingles Vaccine Study
While there is an existing Shingles vaccine, it is not 100% effective and it is not widely available in many countries because it is costly ... -
A Phase 1b/2a randomized double-blind placebo-controlled parallel-group dose-escalation study to investigate the safety tolerability pharmacokinetics pharmacodynamics and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies
Longboard Pharmaceuticals, Inc. has begun a study of an investigational drug called LP352 as a possible treatment for seizures associated with Developmental and Epileptic Encephalopathies ... -
A phase 1b clinical trial of UB-312 in subjects with synucleinopathies
The purpose of this research is to evaluate the safety and tolerability of an investigational vaccine (UB-312), in patients with Multiple System Atrophy (MSA) and ...